Back to search results

REGN7075 and Cemiplimab for Advanced Cancers

This study is testing an investigational drug called REGN7075, both alone and combined with cemiplimab, with or without chemotherapy. It's for adults with advanced solid tumors. The main goals are to understand how safe REGN7075 is, how well it's tolerated, and to find the best dose when combined with cemiplimab. Researchers also want to see how effective these treatments are at shrinking tumors. You could be eligible if you have a confirmed advanced cancer and a good general health status (ECOG performance status of 0 or 1). Some parts of the study are for people who haven't received prior PD-1/PD-L1 immunotherapy. The study plans to enroll up to 548 participants.

Study design
This interventional study is exploring different combinations of REGN7075 and cemiplimab, with or without chemotherapy, in up to 548 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your health will be monitored for adverse events for approximately 90 days after your last dose, and potentially for up to 5 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04626635

A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers

Active, Not Recruiting
PHASE1Ages 18+InterventionalTreatment
Regeneron Pharmaceuticals
~548 participants
Updated 2026-07-02 on ClinicalTrials.gov
What's tested:REGN7075CemiplimabPlatinum-based doublet chemotherapyBevacizumabTrifluridine-tipiracil

At a glance

Recruiting sites
0 of 54 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
The incidence of Dose-Limiting Toxicities (DLTs) during the DLT period
Measured over Up to 6 weeks
+5 more outcomes measured

Conditions

Advanced Solid Tumors

Explore related trials

Solid NeoplasmProgrammed Cell Death 1 Ligand 1

Where it's being run

54 sites across 34 states
Spain6
Israel5
California3
Turkey (Türkiye)3
Florida2
Ohio2
Tennessee2
Texas2

Study leadership

  • Clinical Trial Management · STUDY_DIRECTOR · Regeneron Pharmaceuticals

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

What this trial measures

  • The incidence of Dose-Limiting Toxicities (DLTs) during the DLT periodUp to 6 weeks

    Dose escalation

  • Incidence and severity of Treatment-Emergent Adverse Events (TEAEs)Approximately 90 days from last dose; up to 5 years

    Dose escalation

  • Incidence and severity of Adverse Events of Special Interest (AESIs)Approximately 90 days from last dose; up to 5 years

    Dose escalation

  • Incidence and severity of Serious Adverse Events (SAEs)Approximately 90 days from last dose; up to 5 years

    Dose escalation

  • Incidence and severity of grade ≥3 laboratory abnormalitiesApproximately 90 days from last dose; up to 5 years

    Dose escalation

  • Objective Response Rate (ORR)Up to 5 years

    Dose expansion